ALTEROLA BIOTECH INC.
Healthcare · Medicinal Chemicals & Botanical Products · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 |
| Operating income | −$2.1M | −$2.0M | −$6.5M | −$309,500 | −$329,511 | −$258,453 |
| Net income | −$2.4M | −$2.1M | −$6.5M | −$343,033 | −$250,511 | −$258,702 |
| Total assets | $3,663 | $12.0M | $12.1M | $519 | $15,273 | $14,742 |
| Total liabilities | $1.3M | $2.3M | $1.2M | $389,721 | $338,494 | $217,452 |
| Equity | −$1.3M | $9.8M | $10.9M | $136 | −$323,221 | −$202,710 |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 1.47B | 807.0M | 807.0M | 754.3M | 331.0M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- —
- Net margin
- —
- Return on equity
- 178.6%
- Return on assets
- −64820.6%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 36398.1%
- Debt / equity
- —
- Book value / share
- $-0.00
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -17300.11distress
- Accruals / assets
- −25315.1%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Feb 14, 2025
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2024
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2024
- NT 10-Kmissed a reporting deadline ↗Jun 28, 2024
- NT 10-Qmissed a reporting deadline ↗Feb 14, 2024
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or disposition · Director / officer change · Regulation FD disclosureJun 30, 2025
- Prior financials not reliable (restatement)Sep 30, 2024
- Entered a material agreement · New financial obligationSep 12, 2024
- Unregistered equity sale · Changed auditorOct 20, 2023
- Director / officer changeOct 17, 2023
- Entered a material agreementSep 19, 2023
- Director / officer changeJun 22, 2023
- Entered a material agreement · Director / officer changeOct 7, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-15DJun 30, 2025
- 8-KFORM 8-KJun 30, 2025
- NT 10-QFeb 14, 2025
- 10-QFORM 10-QNov 29, 2024
- 10-Q/AFORM 10-Q/ANov 25, 2024
- NT 10-QNov 14, 2024
- 8-KFORM 8-KSep 30, 2024
- 8-KFORM 8-KSep 12, 2024
- 10-QFORM 10-QAug 15, 2024
- NT 10-QAug 14, 2024
- 10-KFORM 10-KJul 18, 2024
- NT 10-K10-K EXTENSIONJun 28, 2024
- 10-Q/AFeb 21, 2024
- 10-QFeb 20, 2024
- NT 10-QFeb 14, 2024
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.